Peak6 LLC Invests $707,000 in Cellebrite DI Ltd. (NASDAQ:CLBT)

PEAK6 LLC acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,099 shares of the company's stock, valued at approximately $707,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. FMR LLC increased its position in shares of Cellebrite DI by 89.1% during the fourth quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after buying an additional 5,004,587 shares during the period. True Wind Capital Management L.P. raised its position in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. Invesco Ltd. bought a new stake in shares of Cellebrite DI during the fourth quarter valued at approximately $32,700,000. Principal Financial Group Inc. bought a new position in Cellebrite DI in the third quarter worth $23,402,000. Finally, Lord Abbett & CO. LLC purchased a new position in Cellebrite DI during the third quarter valued at $11,523,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

Shares of CLBT stock traded up $0.07 during trading hours on Friday, reaching $19.63. The company had a trading volume of 337,842 shares, compared to its average volume of 1,407,548. The firm has a market cap of $4.70 billion, a PE ratio of -14.10, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The business has a fifty day moving average price of $18.75 and a 200-day moving average price of $20.10. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on CLBT. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, Lake Street Capital raised their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.